aTyr Pharma, Inc. (LIFE)
| Market Cap | 72.29M |
| Revenue (ttm) | 2.39M |
| Net Income (ttm) | -25.13M |
| Shares Out | 14.10M |
| EPS (ttm) | -2.29 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 21 |
| Last Price | $4.33 |
| Previous Close | $4.50 |
| Change ($) | -0.17 |
| Change (%) | -3.78% |
| Day's Open | 4.54 |
| Day's Range | 4.33 - 4.54 |
| Day's Volume | 50,888 |
| 52-Week Range | 2.93 - 8.33 |
Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2.
Atyr Pharma (LIFE) delivered earnings and revenue surprises of -50.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter.
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 3:00pm PT Panel discussion on steroids and sarcoidosis to be held on Tuesday, April 27 at 12:00pm ET / 3:00pm PT
aTyr Pharma Inc (NASDAQ: LIFE) and Lonza Group Ltd (OTCMKTS: LZAGF) have agreed to manufacture ATYR2810, aTyr's monoclonal antibody targeting Neuropilin-2 (NRP2) that is currently in preclinical develop...
Findings demonstrate tumor inhibitory effects of ATYR2810 when used as a monotherapy or in combination with chemotherapy in models of non-small cell lung cancer.
Shares of aTyr Pharma (NASDAQ:LIFE) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 69.48% over the past year to ($0.47), which beat the est...
Completed enrollment of ATYR1923 clinical trial in patients with pulmonary sarcoidosis. Data is expected in the third quarter.
Atyr Pharma (LIFE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Atyr Pharma (LIFE) stock is taking off on Tuesday after getting a price target update from Roth Capital analyst Zegbeh Jallah. The post LIFE Stock: Increased Price Target Gives aTyr Pharma Shares a Big ...
These seven names have shown important insider trading signals after their rallies, meaning some insiders are taking profits in these stocks. The post 7 Stocks With Important Insider Trading Signals Tha...
aTyr Pharma Inc (NASDAQ: LIFE) has initiated two discovery programs from its tRNA synthetase platform that will investigate the functionality of selected fragments of Alanyl-tRNA Synthetase (AARS) and A...
Advancement of selected AARS and DARS fragments primarily targeting cancer
SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathwa...
Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathwa...
Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients.
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2020 Results - Earnings Call Transcript
C omplete s e nrollment of ATYR1923 c linical t rial in patients with COVID-19 s evere r espiratory c omplications . Topline data is expected at turn of calendar year.
Peer-reviewed paper supports aTyr's antibody program .
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathwa...
Although penny stocks come with an added element of risk, investing in the right stocks could set you up for massive gains in the future. Here are the best penny stocks to buy right now.
Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese healthy volunteers Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in Japanese...
Aspire Capital commits to purchase up to $20 Million of Common Stock over a period of up to 30 months.
These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential appeared fir...
SAN DIEGO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological ...
SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (the “Company”) (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on nove...
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q2 2020 Results - Earnings Call Transcript
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 5.48% and -52.75%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to host conference call and webcast today, August 13, at 5:00 p.m. EDT / 2:00 p.m. PDT
Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy volunteers in Japan. Study will evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in healthy...
Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on August 13th at 5:00 pm EDT / 2:00 pm PDT
Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Poster details data from aTyr’s preclinical, domain specific Neuropilin-2 (NRP2) antibody program showing antibodies may increase sensitivity to chemotherapy in triple-negative breast cancer.
Discovery that Neuropilin b1 domain acts as a binding site for SARS-CoV-2 Spike protein and aids viral entry. Lead therapeutic candidate, ATYR1923, modulates Neuropilin pathway to dampen inflammatory...
Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S. Trial opens for enrollment of hospitalized patients at multiple centers throughout the U.S.
Atyr Pharma (LIFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q1 2020 Results - Earnings Call Transcript
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 238.89% and 83.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT Company to host conference call and webcast today, May 12, at 5:00 p.m. EDT / 2:00 p.m. PDT
Abstracts originally accepted for presentation at the 2020 American Thoracic Society (ATS) International Conference
SAN DIEGO, April 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological ...
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and 69.41%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2019 Results - Earnings Call Transcript
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 3.14% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Grant awarded by the Hong Kong Government's Innovation and Technology Commission under the Partnership Research Program
SAN DIEGO, March 10, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological ...
About LIFE
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product ATYR1923 is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also d... [Read more...]
| Industry Biotechnology | IPO Date May 7, 2015 |
| CEO Sanjay Shukla | Employees 40 |
| Stock Exchange NASDAQ | Ticker Symbol LIFE |
Financial Performance
In 2020, aTyr Pharma's revenue was $10.46 million, an increase of 2,377.49% compared to the previous year's $422,000. Losses were -$16.22 million, -31.26% less than in 2019.
Analyst Forecasts
According to 3 analysts, the average rating for aTyr Pharma stock is "Buy." The 12-month stock price forecast is 16.00, which is an increase of 269.52% from the latest price.